Advertisement


Jennifer Woyach, MD, on Relapsed/Refractory CLL: Next-Generation BTK Inhibitor

ASH 2025

Advertisement

Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, reviews phase I data on rocbrutinib, a new selective next-generation inhibitor of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and prior exposure to BTK and/or BCL-2 inhibitors (Abstract 87). 



Related Videos

Multiple Myeloma

Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab

Andrew Portuguese, MD, of Fred Hutchinson Cancer Center, discusses findings from a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium looking at the real-world safety and efficacy of the BCMA-CD3 bispecific antibody elranatamab (Abstract 136).  

Myelodysplastic Syndromes

Amer Zeidan, MBBS, on Lower-Risk MDS: Treatment-Emergent Cytopenias and Clinical Response

Amer Zeidan, MBBS, of Yale School of Medicine, discusses findings from an analysis of the IMerge trial, which explored the possible association between imetelstat-related cytopenias and hemoglobin increasea measure linked to red blood cell transfusion independence achievement—in patients with lower-risk myelodysplastic syndromes (MDS) (Abstract 490). 

Leukemia

Nitin Jain, MD, on a Triplet Regimen for Richter Transformation

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, reviews findings from a phase II trial of pirtobrutinib, venetoclax, and obinutuzumab for patients with Richter transformation (Abstract 89). 

Leukemia

Jayastu Senapati, MBBS, on B-Cell ALL: Brexucabtagene Autoleucel as Consolidation Therapy

Jayastu Senapati, MBBS, of The University of Texas MD Anderson Cancer Center, presents initial results from a phase II trial of brexucabtagene autoleucel as consolidation therapy in front-line high-risk B-cell acute lymphoblastic leukemia (B-ALL) or relapsed/refractory B-ALL after cytoreduction (Abstract 1573). 

Leukemia

Anand Patel, MD, on Ph-Positive ALL: TKI Plus Inotuzumab Ozogamicin–Based Therapy

Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicinbased therapy resulted in major molecular response in patients newly diagnosed with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) (Abstract 441). 

Advertisement

Advertisement




Advertisement